Hematology

Advanced Treatment: Understanding IV Iron Options

At a Glance

IV iron can treat iron deficiency anemia when oral iron is not tolerated, absorbed, or fast enough. Modern products are usually safe with monitoring, but Injectafer has a higher risk of prolonged low phosphate, so at-risk patients may need blood tests before and after treatment.

While oral iron is the standard starting point for most people, there are situations where your body simply cannot absorb enough iron through the digestive tract. In these cases, Intravenous (IV) Iron—iron delivered directly into your bloodstream—is a highly effective alternative ^[1]^[2].

When is IV Iron Necessary?

Your doctor may recommend IV iron if you fall into one of the following categories:

Oral Intolerance: You experience severe, unmanageable side effects from iron pills ^[3]^[1].
Malabsorption: You have a condition that prevents your gut from absorbing iron, such as Celiac Disease, active Inflammatory Bowel Disease (IBD), or previous bariatric (weight-loss) surgery ^[3]^[4].
Need for Rapid Correction: You require a rapid increase in your iron levels, such as during advanced pregnancy or shortly before a planned surgery ^[5]^[6].
Chronic Illness: You have conditions like Chronic Kidney Disease or Heart Failure, where inflammation effectively blocks oral iron absorption ^[1]^[2].

Common IV Iron Options

There are several types of IV iron, differing largely in how much iron can be administered safely in a single visit:

Iron Sucrose (Venofer): A well-established option that typically requires multiple smaller infusions to reach a full replacement dose ^[7].
Ferric Carboxymaltose (Injectafer) and Ferric Derisomaltose (Monoferric): These formulations allow for high doses of iron to be delivered in one or two short infusions ^[7]^[8]. Older low-molecular-weight iron dextran is also an option, though it requires a “test dose” to check for immediate reactions ^[7]^[9].

Safety and Infusion Reactions

Many patients worry about severe allergic reactions (anaphylaxis). While this was a major concern with older, high-molecular-weight iron products that are no longer used, severe true allergies are rare with modern formulations ^[10].

However, all IV iron must be administered in a setting where trained staff can monitor you. Nonallergic “infusion-related reactions” can occur. You should immediately report symptoms like flushing, chest tightness, wheezing, back or joint pain, dizziness, or swelling during your infusion. Often, these symptoms resolve simply by slowing down the IV drip rate, but medical staff must evaluate them ^[10]^[9].

A Critical Safety Note: The Phosphate Risk

While IV iron is generally safe, one specific formulation—Ferric Carboxymaltose (FCM), sold under the brand name Injectafer—carries a unique risk that you and your doctor should discuss ^[11]^[12].

FCM can trigger your body to release a hormone called FGF23 ^[13]. This hormone tells your kidneys to flush phosphate out of your body through your urine, leading to hypophosphatemia (low phosphate levels) ^[14]^[11].

Frequency: Depending on the clinical trial and dose, a significant majority of patients receiving FCM develop a drop in phosphate, compared to a much smaller percentage receiving formulations like Ferric Derisomaltose ^[12]^[15].
Severity: While sometimes mild and temporary, a subset of patients experience severe and prolonged drops in phosphate ^[14].
Symptoms: Severe low phosphate can cause extreme fatigue, muscle weakness, and bone pain ^[16]^[17].
Long-term Risk: If missed, particularly with repeated high-dose infusions, it can lead to osteomalacia—a painful softening of the bones that can cause fractures ^[18]^[17].

If you are receiving Injectafer (FCM), discuss a risk-based monitoring plan for your phosphate levels with your clinician. Routine testing is strongly recommended if you have risk factors like vitamin D deficiency or need repeated doses ^[18]^[19]. Other IV irons have a lower risk of this specific complication, though the risk is not zero ^[12]^[20].

Common questions in this guide

When might someone with iron deficiency anemia need IV iron?

IV iron may be recommended when iron pills cause severe side effects, the digestive tract cannot absorb enough iron, or a rapid increase is needed before surgery or during advanced pregnancy. It may also be considered in chronic kidney disease or heart failure, where inflammation can make oral iron less effective.

How do the main IV iron treatments differ?

Iron sucrose, sold as Venofer, usually requires several smaller infusions. Ferric carboxymaltose, sold as Injectafer, and ferric derisomaltose, sold as Monoferric, can often deliver a larger dose in one or two visits, while low-molecular-weight iron dextran may require a test dose.

What symptoms should I report during an IV iron infusion?

Tell the infusion staff immediately about flushing, chest tightness, wheezing, back or joint pain, dizziness, or swelling. These reactions may improve when the drip is slowed, but the staff should assess you before treatment continues.

Why is Injectafer linked to low phosphate?

Injectafer, also called ferric carboxymaltose, can increase a hormone that makes the kidneys remove more phosphate in urine. A substantial drop may cause fatigue, muscle weakness, or bone pain; severe, prolonged low phosphate can soften bones and increase fracture risk.

Who may need phosphate monitoring after Injectafer?

Ask your clinician about baseline and follow-up phosphate testing if you receive Injectafer, especially if you have vitamin D deficiency, need repeated high-dose infusions, or have had weight-loss surgery. Other IV iron products have a lower risk of this problem, but the risk is not zero.

Get notified when new evidence is published on iron deficiency anemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

IV iron may be considered when oral iron causes severe side effects, is poorly absorbed, a rapid correction is needed, or chronic illness limits its effectiveness.
Iron sucrose usually requires multiple smaller infusions, while ferric carboxymaltose and ferric derisomaltose often allow larger doses in one or two visits.
Severe allergic reactions to modern IV iron products are rare, but trained staff should monitor every infusion and evaluate symptoms such as wheezing, chest tightness, dizziness, or swelling.
Ferric carboxymaltose, sold as Injectafer, can cause low phosphate, which may lead to fatigue, muscle weakness, bone pain, or, rarely, bone softening and fractures.
Patients receiving Injectafer may need risk-based phosphate testing, especially with vitamin D deficiency, repeated doses, or previous weight-loss surgery.

References (20)

1
Iron Deficiency in Adults: A Review.
Auerbach M, DeLoughery TG, Tirnauer JS
JAMA 2025; (333(20)):1813-1823 doi:10.1001/jama.2025.0452.
PMID: 40159291
2
Efficacy of oral vs. intravenous iron for the treatment of iron deficiency anemia in different conditions: A systematic review and meta-analysis.
Zhao C, He W
Biomedical reports 2026; (24(1)):11 doi:10.3892/br.2025.2084.
PMID: 41282507
3
AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review.
DeLoughery TG, Jackson CS, Ko CW, Rockey DC
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024; (22(8)):1575-1583 doi:10.1016/j.cgh.2024.03.046.
PMID: 38864796
4
High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
Schoeb M, Räss A, Frei N, et al.
Obesity surgery 2020; (30(7)):2659-2666 doi:10.1007/s11695-020-04544-x.
PMID: 32221822
5
Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum.
Breymann C, Honegger C, Hösli I, Surbek D
Archives of gynecology and obstetrics 2017; (296(6)):1229-1234 doi:10.1007/s00404-017-4526-2.
PMID: 28940095
6
Management of Perioperative Iron Deficiency Anemia.
Gómez-Ramírez S, Bisbe E, Shander A, et al.
Acta haematologica 2019; (142(1)):21-29 doi:10.1159/000496965.
PMID: 30970362
7
A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.
Pollock RF, Muduma G
ClinicoEconomics and outcomes research : CEOR 2017; (9()):475-483 doi:10.2147/CEOR.S139525.
PMID: 28848355
8
Time-dependent trade-offs among intravenous iron formulations for iron-deficiency anemia: a longitudinal systematic review and network meta-analysis.
de Azevedo Filho FM, Fachi MM, Oliveira LA, et al.
Hematology, transfusion and cell therapy 2026; (48(2)):106435 doi:10.1016/j.htct.2026.106435.
PMID: 41921282
9
Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study.
Dave CV, Brittenham GM, Carson JL, Setoguchi S
Annals of internal medicine 2022; (175(5)):656-664 doi:10.7326/M21-4009.
PMID: 35344378
10
Clinical data for intravenous iron - debunking the hype around hypersensitivity.
Achebe M, DeLoughery TG
Transfusion 2020; (60(6)):1154-1159 doi:10.1111/trf.15837.
PMID: 32479668
11
Randomized trial of intravenous iron-induced hypophosphatemia.
Wolf M, Chertow GM, Macdougall IC, et al.
JCI insight 2018; (3(23)).
PMID: 30518682
12
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M, Rubin J, Achebe M, et al.
JAMA 2020; (323(5)):432-443 doi:10.1001/jama.2019.22450.
PMID: 32016310
13
Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
Frazier R, Hodakowski A, Cai X, et al.
Bone 2020; (141()):115559 doi:10.1016/j.bone.2020.115559.
PMID: 32730929
14
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
Schaefer B, Zoller H, Wolf M
The Journal of clinical endocrinology and metabolism 2022; (107(4)):1009-1019 doi:10.1210/clinem/dgab852.
PMID: 34850000
15
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
Schaefer B, Tobiasch M, Viveiros A, et al.
British journal of clinical pharmacology 2021; (87(5)):2256-2273 doi:10.1111/bcp.14643.
PMID: 33188534
16
Indications for the evaluation and supplementation of hypophosphatemia: an umbrella systematic review of reviews and guidelines.
Netzer S, Büchel L, Büchi AE, Aubert CE
BMC medicine 2025; (23(1)):591 doi:10.1186/s12916-025-04415-1.
PMID: 41146174
17
Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
Vilaca T, Velmurugan N, Smith C, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2022; (37(6)):1188-1199 doi:10.1002/jbmr.4558.
PMID: 35426179
18
Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement.
Rosano G, Ezekowitz J, Nemeth E, et al.
Journal of clinical medicine 2025; (14(14)) doi:10.3390/jcm14144861.
PMID: 40725553
19
[Hypophosphatemia after injectable iron treatments in adults: Comparison between ferric carboxymaltose and iron sucrose].
Grino M, Rigaux M, Lagarde AV, et al.
Annales pharmaceutiques francaises 2023; (81(5)):790-800 doi:10.1016/j.pharma.2023.03.003.
PMID: 36963655
20
In-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution.
von Brackel FN, Grambeck J, Barvencik F, et al.
JBMR plus 2024; (8(12)):ziae139 doi:10.1093/jbmrpl/ziae139.
PMID: 39659775

This page is for informational purposes only and does not constitute medical advice. Discuss IV iron selection, infusion reactions, and phosphate monitoring with your clinician.